{"id":"eldecalcitol","rwe":[{"pmid":"41833832","year":"2026","title":"Sympathetic overactivity-induced type H endothelial cell senescence contributes to the impairment of vascularized osteogenesis by PKM2-mediated glycolysis in preclinical stages of Alzheimer's mice.","finding":"","journal":"Bone","studyType":"Clinical Study"},{"pmid":"41828612","year":"2026","title":"Vitamin D Receptor Signaling and Ligand Modulation: Molecular Mechanisms and Therapeutic Implications.","finding":"","journal":"International journal of molecular sciences","studyType":"Clinical Study"},{"pmid":"41765491","year":"2026","title":"[Relationship between Hypercalcemia and Renal Function with Eldecalcitol].","finding":"","journal":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","studyType":"Clinical Study"},{"pmid":"41677837","year":"2026","title":"Trends in the incidence of secondary hip fractures and osteoporosis treatment in Japan (FY2012-FY2023).","finding":"","journal":"Journal of bone and mineral metabolism","studyType":"Clinical Study"},{"pmid":"41568387","year":"2025","title":"Comparative effectiveness of bone-protective interventions for aromatase inhibitors-induced bone loss in postmenopausal women with early breast cancer: a network meta-analysis.","finding":"","journal":"Frontiers in oncology","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Vitamin D3 receptor","category":"target"},{"label":"VDR","category":"gene"},{"label":"Active","category":"status"},{"label":"Osteoporosis","category":"indication"},{"label":"Chugai Pharmaceutical Co., Ltd","category":"company"},{"label":"Bone Density Conservation Agents","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":272.442,"date":"","count":110,"signal":"Osteonecrosis of jaw","source":"DrugCentral FAERS","actionTaken":"Reported 110 times (LLR=272)"},{"llr":238.386,"date":"","count":96,"signal":"Hypercalcaemia","source":"DrugCentral FAERS","actionTaken":"Reported 96 times (LLR=238)"},{"llr":231.906,"date":"","count":149,"signal":"Renal impairment","source":"DrugCentral FAERS","actionTaken":"Reported 149 times (LLR=232)"},{"llr":169.517,"date":"","count":107,"signal":"Interstitial lung disease","source":"DrugCentral FAERS","actionTaken":"Reported 107 times (LLR=170)"},{"llr":120.918,"date":"","count":41,"signal":"Femoral neck fracture","source":"DrugCentral FAERS","actionTaken":"Reported 41 times (LLR=121)"},{"llr":100.888,"date":"","count":42,"signal":"Spinal compression fracture","source":"DrugCentral FAERS","actionTaken":"Reported 42 times (LLR=101)"},{"llr":87.516,"date":"","count":149,"signal":"Fall","source":"DrugCentral FAERS","actionTaken":"Reported 149 times (LLR=88)"},{"llr":86.339,"date":"","count":50,"signal":"Cerebral infarction","source":"DrugCentral FAERS","actionTaken":"Reported 50 times (LLR=86)"},{"llr":86.179,"date":"","count":59,"signal":"Hepatic function abnormal","source":"DrugCentral FAERS","actionTaken":"Reported 59 times (LLR=86)"},{"llr":76.859,"date":"","count":43,"signal":"Osteomyelitis","source":"DrugCentral FAERS","actionTaken":"Reported 43 times (LLR=77)"},{"llr":72.296,"date":"","count":46,"signal":"Hypocalcaemia","source":"DrugCentral FAERS","actionTaken":"Reported 46 times (LLR=72)"},{"llr":66.58,"date":"","count":22,"signal":"Atypical femur fracture","source":"DrugCentral FAERS","actionTaken":"Reported 22 times (LLR=67)"},{"llr":65.89,"date":"","count":71,"signal":"Cardiac failure","source":"DrugCentral FAERS","actionTaken":"Reported 71 times (LLR=66)"},{"llr":60.744,"date":"","count":8,"signal":"Fatigue","source":"DrugCentral FAERS","actionTaken":"Reported 8 times (LLR=61)"},{"llr":56.802,"date":"","count":18,"signal":"Drug ineffective","source":"DrugCentral FAERS","actionTaken":"Reported 18 times (LLR=57)"}],"commonSideEffects":[]},"trials":[],"aliases":[],"company":"Chugai Pharmaceutical Co., Ltd","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ELDECALCITOL","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:09:03.994294+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:09:10.237913+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ELDECALCITOL","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:09:11.011155+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Vitamin D receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:09:11.563068+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297608/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:09:11.471743+00:00"}},"allNames":["eldecalcitol","ED-71"],"offLabel":[],"synonyms":["eldecalcitol","ED-71"],"timeline":[{"date":"2011-01-21","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Chugai Pharmaceutical Co., Ltd)"}],"approvals":[{"date":"2011-01-21","orphan":false,"company":"Chugai Pharmaceutical Co., Ltd","regulator":"PMDA"}],"ecosystem":[{"indication":"Osteoporosis","otherDrugs":[{"name":"abaloparatide","slug":"abaloparatide","company":"Radius Health Inc"},{"name":"calcium citrate","slug":"calcium-citrate","company":""},{"name":"calcium gluconate","slug":"calcium-gluconate","company":""},{"name":"calcium phosphate","slug":"calcium-phosphate","company":""}],"globalPrevalence":200000000}],"mechanism":{"target":"Vitamin D3 receptor","targets":[{"gene":"VDR","source":"DrugCentral","target":"Vitamin D3 receptor","protein":"Vitamin D3 receptor"}],"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Eldecalcitol acts as a selective agonist of the Vitamin D3 receptor, activating the VDR-RXR complex and initiating a signaling cascade that regulates the expression of genes involved in bone metabolism, including osteocalcin and alkaline phosphatase."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5169","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ELDECALCITOL","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ELDECALCITOL","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:57:47.688273","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:09:13.320143+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"calcifediol","drugSlug":"calcifediol","fdaApproval":"1980-08-05","patentExpiry":"Sep 7, 2030","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"calcipotriene","drugSlug":"calcipotriene","fdaApproval":"1993-12-29","patentExpiry":"May 7, 2028","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"calcitriol","drugSlug":"calcitriol","fdaApproval":"1978-08-17","genericCount":18,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"colecalciferol","drugSlug":"colecalciferol","fdaApproval":"2000-05-18","relationship":"same-target"},{"drugName":"doxercalciferol","drugSlug":"doxercalciferol","fdaApproval":"1999-06-09","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"ergocalciferol","drugSlug":"ergocalciferol","fdaApproval":"1941-01-11","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"paricalcitol","drugSlug":"paricalcitol","fdaApproval":"1998-04-17","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-target"}],"genericName":"eldecalcitol","indications":{"approved":[{"name":"Osteoporosis","source":"DrugCentral","snomedId":64859006,"regulator":"FDA","usPrevalence":10000000,"globalPrevalence":200000000,"prevalenceMethod":"curated","prevalenceSource":"IOF, 2023"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"calcifediol","brandName":"calcifediol","genericName":"calcifediol","approvalYear":"1980","relationship":"same-target"},{"drugId":"calcipotriene","brandName":"calcipotriene","genericName":"calcipotriene","approvalYear":"1993","relationship":"same-target"},{"drugId":"calcitriol","brandName":"calcitriol","genericName":"calcitriol","approvalYear":"1978","relationship":"same-target"},{"drugId":"colecalciferol","brandName":"colecalciferol","genericName":"colecalciferol","approvalYear":"2000","relationship":"same-target"},{"drugId":"doxercalciferol","brandName":"doxercalciferol","genericName":"doxercalciferol","approvalYear":"1999","relationship":"same-target"},{"drugId":"ergocalciferol","brandName":"ergocalciferol","genericName":"ergocalciferol","approvalYear":"1941","relationship":"same-target"},{"drugId":"paricalcitol","brandName":"paricalcitol","genericName":"paricalcitol","approvalYear":"1998","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT07063797","phase":"NA","title":"Study on the Intervention Effect of Denosumab on High-Risk Patients With Osteoporotic Fractures in Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2026-02-01","conditions":["Type 2 Diabetes","Osteoporosis","Fractures"],"enrollment":358,"completionDate":"2027-07-31"},{"nctId":"NCT05884372","phase":"PHASE4","title":"Efficacy and Safety of Combination Denosumab With Eldecalcitol for Postmenopausal Women With Osteoporosis.(ESCORT)","status":"COMPLETED","sponsor":"Xi'an Honghui Hospital","startDate":"2023-08-24","conditions":["Osteoporosis in Postmenopausal Women"],"enrollment":100,"completionDate":"2025-07-16"},{"nctId":"NCT06537115","phase":"PHASE4","title":"Clinical Intervention of Idecalcitol Combined With Whey Protein Powder and Exercise for Sarcopenia","status":"RECRUITING","sponsor":"Zhejiang Provincial People's Hospital","startDate":"2024-06-16","conditions":["Sarcopenia"],"enrollment":450,"completionDate":"2027-05-31"},{"nctId":"NCT05902078","phase":"PHASE4","title":"Eldecalcitol and Calcitriol in Postmenopausal Women With Low Bone Mineral Density or Mild Osteoporosis","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University Affiliated Sixth People's Hospital","startDate":"2023-09-27","conditions":["Low Bone Mineral Density","Postmenopausal Osteoporosis"],"enrollment":300,"completionDate":"2025-12"},{"nctId":"NCT06385093","phase":"PHASE4","title":"A Study on the Prevention and Treatment of GIOP With Eldecalcitol","status":"NOT_YET_RECRUITING","sponsor":"Chinese SLE Treatment And Research Group","startDate":"2024-06","conditions":["Rheumatoid Arthritis","Osteoporosis","Osteopenia"],"enrollment":314,"completionDate":"2026-03"},{"nctId":"NCT05433207","phase":"","title":"Post-Marketing Drug Intensive Monitoring Surveillance of EDIROL in Patients With Postmenopausal Osteoporosis","status":"UNKNOWN","sponsor":"Chugai Pharmaceutical","startDate":"2022-08-01","conditions":["Postmenopausal Osteoporosis"],"enrollment":1000,"completionDate":"2025-01-31"},{"nctId":"NCT05406050","phase":"PHASE1","title":"Bioequivalence Study of Eldecalcitol Soft Capsule in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2020-10-20","conditions":["Healthy"],"enrollment":58,"completionDate":"2021-07-15"},{"nctId":"NCT02306187","phase":"PHASE1","title":"The Effectiveness of Eldecalcitol in the Bisphosphonate Non-respondered-patients With Osteoporosis","status":"UNKNOWN","sponsor":"Shinshu University","startDate":"2014-12","conditions":["Osteoporosis"],"enrollment":100,"completionDate":"2024-12"},{"nctId":"NCT01974167","phase":"NA","title":"Eldecalcitol for GLucocorticoid Induced OsteopoRosIs Versus Alfacalcidol","status":"UNKNOWN","sponsor":"e-GLORIA trial Protocol Review Committee","startDate":"2013-12","conditions":["Osteoporosis"],"enrollment":400,"completionDate":""},{"nctId":"NCT00144456","phase":"PHASE3","title":"A New Active Vitamin D, ED-71 for Osteoporosis","status":"COMPLETED","sponsor":"Chugai Pharmaceutical","startDate":"2004-09","conditions":["Osteoporosis"],"enrollment":1056,"completionDate":"2008-10"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"I2JP8UE90H","CHEBI":"CHEBI:73927","INN_ID":"8867","UMLSCUI":"C2828245","chemblId":"CHEMBL4297608","ChEMBL_ID":"CHEMBL4297608","KEGG_DRUG":"D07578","DRUGBANK_ID":"DB05295","PDB_CHEM_ID":"ED9","PUBCHEM_CID":"6918141","IUPHAR_LIGAND_ID":"2783","MESH_SUPPLEMENTAL_RECORD_UI":"C547512"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Chugai Pharmaceutical Co., Ltd","relationship":"Current Owner"}],"publicationCount":227,"therapeuticAreas":["Metabolic"],"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 13","pmid":"41833832","title":"Sympathetic overactivity-induced type H endothelial cell senescence contributes to the impairment of vascularized osteogenesis by PKM2-mediated glycolysis in preclinical stages of Alzheimer's mice.","journal":"Bone"},{"date":"2026 Mar 4","pmid":"41828612","title":"Vitamin D Receptor Signaling and Ligand Modulation: Molecular Mechanisms and Therapeutic Implications.","journal":"International journal of molecular sciences"},{"date":"2026","pmid":"41765491","title":"[Relationship between Hypercalcemia and Renal Function with Eldecalcitol].","journal":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan"},{"date":"2026 Feb 12","pmid":"41677837","title":"Trends in the incidence of secondary hip fractures and osteoporosis treatment in Japan (FY2012-FY2023).","journal":"Journal of bone and mineral metabolism"},{"date":"2025","pmid":"41568387","title":"Comparative effectiveness of bone-protective interventions for aromatase inhibitors-induced bone loss in postmenopausal women with early breast cancer: a network meta-analysis.","journal":"Frontiers in oncology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"ELDECALCITOL","companyName":"Chugai Pharmaceutical Co., Ltd","companyId":"chugai-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2011-01-21T00:00:00.000Z","mah":"Chugai Pharmaceutical Co., Ltd","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:09:13.320143+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}